Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

Figure 3

Predicted risk of recurrence over time based on cytoplasmic intensity and nuclear fraction of cyclin D 1 , comparing two subgroups. (a) In all patients, no significant difference in recurrence risk was observed between low and high cytoplasmic expression. (b) Patients showing a nuclear fraction of less than 1% positive cyclin D1 nuclei had an increased risk of recurrence compared with a fraction of 1 to 100%, in all patients. (c) In patients exhibiting nonamplified tumours, high cytoplasmic expression was associated with a reduced risk of recurrence. (d) A fraction of cyclin D1-positive nuclei lower than 1% was associated with a higher recurrence risk also in patients showing nonamplified tumours.

Back to article page